Agendia is a leading precision oncology company that develops genomic tests to help support physicians faced with complex treatment decisions. MammaPrint®, the 70-gene breast cancer recurrence assay developed for use by physicians as a prognostic marker, is the only FDA-cleared breast cancer recurrence assay backed by peer-reviewed, prospective outcome data and is included in many national and international guidelines. BluePrint®, the 80-gene molecular subtyping assay looks beyond the cell surface to identify Luminal-type, Basal-type and HER2-type breast cancer. Learn more at: www.agendia.com.